A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs Efavirenz (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics; Proof of concept
- 31 Dec 2018 Planned End Date changed from 1 Sep 2020 to 1 May 2020.
- 31 Dec 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Oct 2019.
- 31 Dec 2018 Status changed from not yet recruiting to recruiting.